SEC Form 4 · accession 0000899243-16-013516
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory D Perry
Officer — See Remarks
Period of report
Feb 12, 2016
Accepted (ET)
Feb 17, 2016 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $5.71 | Feb 12, 2016 | A | 200,000 | A | — | Feb 12, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F2The shares of common stock underlying this stock option award will vest in four equal installments as follows: 25% on February 12, 2016, 25% on December 31, 2016, 25% on December 31, 2017, and 25% on December 31, 2018, subject to the Reporting Person's continued employment with the Issuer.
Remarks
Chief Financial and Administration Officer